First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3 beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

Citation
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002). First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors:  Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 45(6), 1292–1299. https://doi.org/10.1021/jm011020u
DOI:
DOI: 10.1021/jm011020u
Year of publication:
2002